Symbiomix and the FDA Approval of Solosec™ [transcript] [audio]

Guest: David L. Stern

Presenter: Neal Howard

Guests Bio: David Stern is the Chief Executive Officer of Symbiomix. Mr. Stern has more than 20 years of biopharmaceutical experience and has launched numerous brands in the U.S. and Global Women’s Health, HIV, and Metabolic markets. He served as the Chief Commercial Officer at Celmatix before joining Symbiomix, responsible for launching the company’s first product, Polaris™. He was also the Executive Vice President of Global Commercial Operations for OvaScience, leading the global launch of Augment®. Before that, he served as Senior Vice President and Head of the Global Business Franchise for Fertility at Merck Serono, responsible for the company’s market leading Fertility portfolio world-wide. Mr. Stern also worked at EMD Serono as Executive Vice President of Endocrinology, managing commercial operations in the Fertility, HIV and Growth Hormone markets. He began his career at Organon Pharmaceutical in Women’s Health. Mr. Stern earned his bachelor’s degree in biology at Brandeis University and holds an MBA from the F.W. Olin School of Business at Babson College. He is a member of the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine, and serves as an independent board member of California Cryobank.

Segment overview: David L. Stern discusses the company’s recent FDA approval of Solosec™ (secnidazole) single dose treatment for bacterial vaginosis and their efforts in bringing innovative medicines to market for prevalent gynecologic infections with serious health consequences.